The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지

Study on the Anti-angiogenic Therapy to Cancer disease with Oriental medicine

혈관신생억제를 통한 종양치료의 한의학적 고찰

  • Song, Kee-Cheol (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Choi, Byung-Ryel (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Lee, Yong-Yeon (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Seo, Sang-Hoon (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Yoo, Hwa-Seung (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Cho, Jung-Hyo (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Lee, Yeon-Weol (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Son, Chang-Gyu (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Cho, Chong-Kwan (Internal medicine Oriental medical hospital of Daejeon Univ.) ;
  • Choi, Woo-Jin (Internal medicine Oriental medical hospital of Daejeon Univ.)
  • 송기철 (대전대학교 부속한방병원 내과) ;
  • 최병렬 (대전대학교 부속한방병원 내과) ;
  • 이용연 (대전대학교 부속한방병원 내과) ;
  • 서상훈 (대전대학교 부속한방병원 내과) ;
  • 유화승 (대전대학교 부속한방병원 내과) ;
  • 조정효 (대전대학교 부속한방병원 내과) ;
  • 이연월 (대전대학교 부속한방병원 내과) ;
  • 손창규 (대전대학교 부속한방병원 내과) ;
  • 조종관 (대전대학교 부속한방병원 내과) ;
  • 최우진 (대전대학교 부속한방병원 내과)
  • Published : 2001.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Angiogenesis is a fundamental process in reproduction and wound healing. Under these condition, neovascularization is tightly regulated. Unregulated angiogenesis may lead to several angiogenic diseases, and is thought to be indispensible for solid tumor growth and metastsis. The construction of new vascular network is a multistep cascade involving basement membrane degradation, endothelial cell proliferation, endothelial cell migration, and tube formation. Newly reported anti-angiogenic agents in oriental medical field have targeted both specific and multistep stages in the angiogenic process. From recent approach in oriental medical field with several herb medicines including activating blood flow and removing blood stasis medicine(活血化瘀藥), it may be possible in the future to develope specific anti-angiogenic agents that offer a less toxic potential therapy for cancer and angiogenic disease.

Keywords

References

  1. Annu. Rev. Med. v.49 Angiogenesis and Tumor Metastasis Bruce, R. Zetter
  2. Am. J. Roentgenol v.42 Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber Ide, A.G.;Baker, N.H.;Warren, S.L.
  3. New Eng. J. Med. v.18 Tumor aniogenesis therapeutic implications Folkman, J.
  4. 동의종양학 최승훈
  5. 경희대학교 대학원 석사 桂枝가 Angiognenesis 억제기전에 미치는 영향 美玧熙
  6. 경희대학교 대학원 석사 鬱金이 Angiogenesis 억제기전에 미치는 영향 成熙根
  7. 경희대학교 대학원 박사 立安散이 Angiogenesis 억제기전에 미치는 여향 李紀龍
  8. 경희대학교 대학원 박사 活絡效靈丹이 Angiogenesis 억제기전에 미치는 영향 羅琪煥
  9. 대전대학교대학원 박사중간 活血化瘀法의 활용을 통한 腫瘍轉移 抑制에 關한 硏究 李淵月
  10. Chemistry & Biology August v.6 Molecular angiogenesis Michael, Klagsbrun;Marsha, A.Moses
  11. Stem Cells v.15 The regulation of neovascularization in matrix metallo-proteinases and their inhibitors Moses, M.A.
  12. J. Biol. Chem. v.267 1-Deoxymannojirimycin inhibits capillary tube formation in vitro;Analysis of N-linked oligosaccharides in bovine capillary endothelial cells Nguyen, M.;Folkman, J.;Bischoff, J.
  13. Development v.125 A Plasticity window for blood vessel remodeling is defined by pericyte coverage of the performed endothelial network and is regulated by PDGF-B and VEGF Benjamin, L.E.;Hemo, I.;Keshet, E.
  14. Enzyme Protein v.49 Plasminogena activators and matrix metallopro-teinases in angiogenesis Mignatti, P.;Rifkin, D.B.
  15. Biochemical Pharmacology v.61 Johan Neyts, Angiogenesis: regulators and clinical applications Liekens, Sandra;Clercq, Erik De
  16. J. Clin Invest v.100 Cell adhiesion and angiogenesis Bischoff, J.
  17. J. Clin Invest v.103 The role of v integrins during angiogenesis:insights into potential mechanism of action and clinical development Eliceiri B.P.;Cheresh, D.A.
  18. Science v.240 Cell and environment interactions in tumor microregions:The multicell spheroid model Sutherland, R.M.
  19. J. Natl. Cancer Inst. v.52 Tumor growth and neovascularization: an experimental model using the rabbit comea Gimbrone, M.A. Jr.;Cotran, R.S.;Leapman, S.B.;Folkman, J.
  20. Nature v.394 Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Carmeliet, P.;Dor, Y.;Herbert, J.M.;Fukumura, D.;Brusslman, K.;Dewerchin, M.;Neeman, M.;Bono, F.;Abramovitch, R.;Maxwell, P.;Koch, C.J.;Ratcliffe, P.;Moons, L.;Jain, R.K.;Collen, D.;Keshert, E.;Keshet, E.
  21. Mol Med v.4 Establishing a link between oncogenes and tumor angiogenesis Kerbel, R.S.;Viloria-Petit, A.;Okada, F.;Rak, J.
  22. The Int. Journal of Biochemistry & Cell Biology v.33 Endogenous angiogenesis inhibitors and their therapeutic implications Yihai, Cao
  23. Cell v.86 Patterns and emerging mechanisms of the aniogenic switch during tumorigenesis Hanahan, D.;Folkman, J.
  24. Am. J. Pathol v.146 Vascular permeability factor/vascular endothelial growth factor, microvascular hyperper-meability, and aniogenesis Dvorak, H.F.;Brown, L.F.;Detmar, M.;Dvorak, A.M.
  25. J. Natl. Cancer Inst. v.85 Expression of basic fibroblast growth factor in primary human renal tumors:correlation with poor survival Nanus, D.M.;Schmitz-Drager, B.J.;Motzer, R.J.(et al.)
  26. Cancer Res. v.57 Expression of the angiogenic factors, vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, plateletderived growth endothelial cell growth factor, placental growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Relf, M.;LeJeune, S.;Scott, P.A.E.(et al.)
  27. Am. J. Pathol v.147 Tumor angiogenesis in advanced stage ovarian arcinoma Hollingsworth, H.C.;Kohn, E.C.;Steinberg, S.M.(et al.)
  28. EXS v.61 Modulation of angiogenesis in vitro Montesano, R.;Pepper, M.S.;Vassalli, J.D.;Orci, L.
  29. Int J Biol Markers v.14 Models for studying angiogenesis in vivo Ribatti, D.;Vacca, A.
  30. Cell v.92 Disruption of angiogenesis by PEX;a noncatalytic metalloproteinase fragment with integrin binding activity Brooks, P.C.;Silletti, S.;Von Schalsca, T.L.;Friedlander, M.;Cheresh, D.A.
  31. J Natl Cancer Inst v.89 Thrombos-pondin-1 expression in bladder cancer:association with p53 alterations, tumor angiogenesis, and tumor progression Grossfeld, G.D.;Ginsberg, D.A.;Stein, J.P.;Bochner, B.H.;Esrig, D.;Groshen, S.;Dunn, M.;Nichols, P.W.;Taylor, C.R.;Skinner, D.G.;Cote, R.J.
  32. Proc Natl Acad Sci USA v.96 Angiostatin binds ATP synthase on the surface of human endothelial cells Moser, T.L.;Stack, M.S.;Asplin, I.;Enghild, J.J.;Hojrup, P.;Everitt, L.;Hubchak, s.;Schnaper, H.W.;Pizzo, S.V.
  33. Cell v.88 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth O'Reilly, M.S.;Boehm, T.;Shing, Y.;Fukai, N.;Vasios, G.;Lane, W.S.;Flynn, E.;Birkhead, J.R.;Olsen, B.R.;Folkman, J.
  34. Nature v.348 Synthetic anologues of fumagillin that inhibit angiogenesis and suppress tumor growth Ingber, D.;Fujita, T.;Kishimoto, S.;Sudo, K.;Kanamaru, T.;Brem, H.;Folkman, J.
  35. Cancer Res v.56 Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo Millauer, B.;Longhi, M.P.;Plate, K.H.;Shawver, L.K.;Risau, W.;Ullrich, A.;Strawn, L.M.
  36. Proc Natl Acad Sci USA v.95 Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate Goldman, C.K.;Kendall, R.L.;Cabrera, G.;Soroceanu, L.;Heike, Y.;Gillespie, G.Y.;Siegal, G.P.;Mao, X.;Bett, A.J.;Huckle, W.R.;Thomas, K.A.;Curiel, D.T.
  37. Cancer Res v.59 Antivascular endothelial growth factor receptor(fetal lier kinase 1)monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tomors Prewett, M.;Huber, J.;Li, Y.;Santiago, A.;O'Connor, W.;King, K.;Overholser, J.;Hooper, A.;Pytowski, B.;Witte, L.;Bohlen, P.;Hicklin, D.J.
  38. Cancer Res v.59 SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(Flk-1/KDR)that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tomor types Fong, T.A.;Shawver, L.K.;Sun, L.;Tang, C.;App, H.;Powell, T.J.;Kin, Y.H.;Schreck, R.;Wang, X.;Risau, W.;Ullrich, A.;Hirth, K.P.;McMahon, G.
  39. J Pediatr Heatol Oncol v.19 Successful treatment of infantile hemangioma with interferon- -2b Chang, E.;Boyd, A.;Nelson, C.C.;Croley, D.;Law, T.;Keough, K.M.;Folkman, J.;Ezekowits, R.A.B.;Castle, V.P.
  40. 黃帝內經 洪元植(編)
  41. 醫林改錯 王淸任
  42. 大田大學校大學院 박사 가미서황환의 항전이와 면역증진에 관한 연구 김성동
  43. Kor. J. Pharmacgn v.31 no.3 한국산 식물자원으로부터 신생혈관 억제제 검색 배기환
  44. Drugs v.58 The rationale and future potential of angiogenesis inhibitors in neoplasia Gasparini, G.
  45. Nature v.390 A cancer therapy resistant to resistance Kerbel, R.S.
  46. J. Biochemistry & Cell Biology v.33 Endogenous angiogenesis inhibitors and their therapeutic implications Yihai, Cao